07:51 AM EDT, 06/13/2025 (MT Newswires) -- Zai Lab ( ZLAB ) said Friday that new data from its preclinical study of ZL-1503 demonstrated the product candidate's potential as a treatment for moderate-to-severe atopic dermatitis, or AD.

The company said results from the preclinical study in non-human primates showed that a single intravenous dose of ZL-1503 "completely inhibited" IL-13-mediated pSTAT6 and IL-31-induced scratching for at least 76 days in all subjects and was well tolerated.